Adial pharmaceuticals announces closing of $10 million financing

Charlottesville, va., feb. 16, 2022 (globe newswire) -- adial pharmaceuticals, inc. (nasdaq: adil; adilw) (“adial” or the “company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately $10 million of the company's common stock and pre-funded warrants, as well as warrants to purchase common stock in a concurrent private placement. the combined effective purchase price for one share of common stock (or pre-funded warrant in lieu thereof) and a warrant to purchase 0.95 shares of common stock was $2.40.
ADIL Ratings Summary
ADIL Quant Ranking